Dec. 21 at 7:39 PM
$ACOG is part of this morning's article titled, "2025 Wrap-Up: Portfolio Thoughts and Looking Ahead" by Anders Research
🔜 ... a chance to be by far and away best in class (e.g. ACOG, IVVD)
Alpha Cognition is down about 20% from my initiation back in May. The story has taken a bit longer to play out than investors and myself were hoping (despite management’s clear guidance to a slow 2025 and an acceleration in 2026), but the core thesis of a best-in-class acetylcholinesterase inhibitor being sold into an Alzheimer’s market that hasn’t received a new symptomatic treatment in two decades, is still very much intact.
In fact, ACOG is becoming one of my favorite companies heading into 2026, especially for the second half of the year (4Q25 earnings call in February might not be stellar), as the stock is now ~50% off of its highs for the year, despite positive developments like ahead-of-schedule agreements with major healthcare insurance plans. The story was always going to take time to play out—long-term care (LTC) facility prescribers are trialing Zunveyl with a small initial set of patients before prescribing at higher rates, which should start to manifest in 2026. I still believe Zunveyl can become a mini version of Aricept (
$2.5+ billion of peak sales), with the obvious threat to that thesis being the arrival of a truly disease-modifying therapy, which is a key point of continual monitoring for ACOG investors.
Still, if 2026 does end up being the year that a disease-modifying therapy bursts onto the scene—which I would say doesn’t look particularly any more likely than past years, though could always happen—there will be multiple years until that product reaches the market, and even when it does, the Alzheimer’s market is so large that I think Zunveyl could continue to carve out a niche (depending on just how good this disease-modifying therapy is).
I will be coming out with a piece talking about the 2026 landscape for disease-modifying Alzheimer’s treatments (key readouts, etc.) in the coming weeks.
ACOG is set for a strong 2026 (particularly Q2 and Q3 earnings should start to get interesting), and I also think it has defensive aspects as a solid, economy-agnostic revenue growth story.
Note: Please consider supporting Anders Research's efforts. Thanks!
Also, if your interest lays in ACOG because of a family member with Alzheimer's, please follow my posts about
$ANVS which is currently enrolling for an FDA P3 Alz drug study as Annovis Bio is a company I have insights on and believe is hurting the biotech community, patients, their families, and investors.
Here's a recent post about Annovis Bio's CEO posted on
$AVXL:
https://stocktwits.com/ForestFoxes/message/639792914
Annovis Bio is going to damage efforts of companies such Anavex Life Sciences Corp. as they continue their efforts for a successful pathway via the FDA. I am also tagging
$CGTX as their appears to be a proxy acting on behalf of Dr. Maccecchini to sway shareholders from Cognition Therapeutics, Inc. over to Annovis Bio based on the buy-line "ANVS's risk/reward is exceptionally good" or some variation of this statement. Nothing could be further from the truth as the CEO appears to be unscrupulous from all of my observations, careless and sloppy with her work based on tracking and help her over the past 5-years, etc.
